scholarly journals Network Analysis of Cancer-focused Association Network Reveals Distinct Network Association Patterns

2014 ◽  
Vol 13s3 ◽  
pp. CIN.S14033
Author(s):  
Yuji Zhang ◽  
Cui Tao

Cancer is a complex and heterogeneous disease. Genetic methods have uncovered thousands of complex tissue-specific mutation-induced effects and identified multiple disease gene targets. Important associations between cancer and other biological entities (eg, genes and drugs) in cancer network, however, are usually scattered in biomedical publications. Systematic analyses of these cancer-specific associations can help highlight the hidden associations between different cancer types and related genes/drugs. In this paper, we proposed a novel network-based computational framework to identify statistically over-expressed subnetwork patterns called network motifs (NMs) in an integrated cancer-specific drug–disease–gene network extracted from Semantic MEDLINE, a database containing extracted associations from MEDLINE abstracts. Eight significant NMs were identified and considered as the backbone of the cancer association network. Each NM corresponds to specific biological meanings. We demonstrated that such approaches will facilitate the formulization of novel cancer research hypotheses, which is critical for translational medicine research and personalized medicine in cancer.

2020 ◽  
Vol 21 (17) ◽  
pp. 6087
Author(s):  
Yunzhen Wei ◽  
Limeng Zhou ◽  
Yingzhang Huang ◽  
Dianjing Guo

Long noncoding RNA (lncRNA)/microRNA(miRNA)/mRNA triplets contribute to cancer biology. However, identifying significative triplets remains a major challenge for cancer research. The dynamic changes among factors of the triplets have been less understood. Here, by integrating target information and expression datasets, we proposed a novel computational framework to identify the triplets termed as “lncRNA-perturbated triplets”. We applied the framework to five cancer datasets in The Cancer Genome Atlas (TCGA) project and identified 109 triplets. We showed that the paired miRNAs and mRNAs were widely perturbated by lncRNAs in different cancer types. LncRNA perturbators and lncRNA-perturbated mRNAs showed significantly higher evolutionary conservation than other lncRNAs and mRNAs. Importantly, the lncRNA-perturbated triplets exhibited high cancer specificity. The pan-cancer perturbator OIP5-AS1 had higher expression level than that of the cancer-specific perturbators. These lncRNA perturbators were significantly enriched in known cancer-related pathways. Furthermore, among the 25 lncRNA in the 109 triplets, lncRNA SNHG7 was identified as a stable potential biomarker in lung adenocarcinoma (LUAD) by combining the TCGA dataset and two independent GEO datasets. Results from cell transfection also indicated that overexpression of lncRNA SNHG7 and TUG1 enhanced the expression of the corresponding mRNA PNMA2 and CDC7 in LUAD. Our study provides a systematic dissection of lncRNA-perturbated triplets and facilitates our understanding of the molecular roles of lncRNAs in cancers.


2009 ◽  
Vol 13 (04) ◽  
pp. 26-63

Interview with Kurt Wüthrich – Why Structural Biology Matters. The PCR Revolution – An Interview with Carl T Wittwer. Viva-University Children's Cancer Centre Opens at NUH. Biotech Crops — The Evergreen Revolution. From Velocity11 to Agilent Automation Solutions — The Revolutionary Road to Automation in Life Sciences. Schering-Plough Sets Up Translational Medicine Research Centre in Singapore.


2010 ◽  
Vol 8 (3) ◽  
pp. 194-201
Author(s):  
Csilla Sipeky ◽  
Gyorgy Keri ◽  
Andras Kiss ◽  
Laszlo Kopper ◽  
Andras Matolcsy ◽  
...  

2019 ◽  
Vol 6 (1) ◽  
Author(s):  
Ibrahim Emam ◽  
Vahid Elyasigomari ◽  
Alex Matthews ◽  
Stelios Pavlidis ◽  
Philippe Rocca-Serra ◽  
...  

2020 ◽  
Vol 6 (8) ◽  
pp. FSO600
Author(s):  
Edward B Maldonado ◽  
Scott Parsons ◽  
Emerson Y Chen ◽  
Alyson Haslam ◽  
Vinay Prasad

Aims, patients & methods: In this retrospective review, we sought to estimate the proportion of patients in the USA with advanced or metastatic cancer who are eligible for and may respond to recommended first-line cytotoxic chemotherapy based on National Comprehensive Cancer Network treatment guidelines. Results: Among 609,640 patients, we estimate 479,823 (78.7%, 95% CI: 78.6–78.8%) may be eligible for cytotoxic chemotherapy while 189,159 out of 609,640 patients (31.0%, 95% CI: 30.9–31.1%) may have achieved treatment response. The average objective response rate from these regimens was 48.6% (range 9.2 to 90.6%). Conclusion: Given the large role of cytotoxic agents in cancer, drug development in this space may remain of interest in specific cancer types, and regulatory approval of novel oncology drugs may justify head-to-head comparisons against cytotoxic regimens.


Sign in / Sign up

Export Citation Format

Share Document